Regenxbio Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, everyone. My name is Gena Wang, I'm a mid-cap biotech analyst at Barclays. It is my great pleasure to introduce our next speaker, Ken Mills from REGENXBIO.
Thanks, Gena. Good afternoon, everyone. Appreciate the opportunity that Gena and the team have afforded us to present on REGENXBIO today. Forward-looking statements and risk factors can be found in more detail in our disclosures on the SEC website.
REGENXBIO: People, plan, science and the mission. Seeking improved lives through the curative potential of gene therapy, the people at REGENXBIO and our partners are currently focused on over 30 programs in preclinical or clinical stages. Inside the company, we have 200 people in Rockville, Maryland, focused on advancing 4 clinical-stage programs. Outside through partnership, we have over 14 clinical-stage programs with some of the most advanced programs on the cusp of a punitive approval here in the first
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |